Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081624 | 0.81 | MAOA (0.39) | ALDH1A1HPGDLMNAMAOAMAOB | |
| SCHEMBL19090941 | 0.78 | MME (0.36) | ALDH1A1TDP1LMNAMAOAMAOB | |
| SCHEMBL19091220 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53 | |
| SCHEMBL3945128 | 0.77 | — | — | |
| SCHEMBL19090787 | 0.77 | — | — | |
| SCHEMBL7950812 | 0.77 | — | — | |
| SCHEMBL3355493 | 0.76 | — | — | |
| SCHEMBL5365359 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TDP1PTPN1CA2SMN1; SMN2 | |
| SCHEMBL6343473 | 0.74 | MEN1 (0.46) | ALDH1A1TDP1PTPN1CA2SMN1; SMN2 | |
| SCHEMBL6633417 | 0.73 | ALDH1A1 (0.40) | ALDH1A1TDP1PTPN1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562113-B2 | Labeled alginate conjugates for molecular imaging applications | BELLEROPHON BCM LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | TAPESTRY PHARMACEUTICALS, INC. | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | MRPL21, QSOX1, MLX | ALDH1A1 820/4885TDP1 3844/4885PTPN1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.